Related Experiment Video
Updated: Jul 15, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin
Sheng Li1, Zuoxing Niu, He Tian
1Shandong Tumor Hospital, Jinan, Shandong Province, China. Yanxun007@263.net
Background/Aims:
To investigate the effects of gemcitabine-oxaliplatin in patients with advanced unresectable hepatocellular carcinoma (HCC).
Methodology:
Forty patients confirmed with unresectable, nonembolizable HCC and objective measurable tumors, had received no prior systemic chemotherapy. All patients enrolled in this study had adequate liver and renal functions, and adequate bone marrow reserve. Gemcitabine (1250 mg/m2) was given on day 1 and oxaliplatin (100 mg/m2) on day 2 via intravenous infusion in each 21-day cycle. If no evidence of disease progression or unacceptable adverse effects occurred, the treatment courses would continue.
Results:
No affirmative response was achieved; partial response (PR) was achieved in 1 patient. Eight patients (20%) had stable diseases with an average duration of 20.2 weeks. The others were rated progression. The average time to progression was 13.9 weeks. The spectra of both hematologic and nonhematologic toxicities were mild, with thrombocytopenia as the dose-related side effect.
Conclusions:
The toxicities of gemcitabine-oxaliplatin were well managed in this study. In view of these treatment results, gemcitabine-oxaliplatin combination therapy with this particular dose regimen should not be considered in patients with advanced hepatocellular carcinoma.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...